Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we predict who can safely lower Anti-Rejection drugs after hand or face transplants?

NCT ID NCT02055521

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked for immune tolerance markers in 18 hand and face transplant recipients (transplanted at least one year prior). Researchers analyzed blood and skin biopsies to find a 'tolerance signature' that might identify patients who could safely reduce their lifelong anti-rejection medication. The goal is to minimize drug side effects while preventing graft rejection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify which transplant recipients can safely lower their anti-rejection drugs, reducing side effects.
What could go wrong
This is a small, observational study (18 people) looking for biological markers, not testing a new treatment. The markers may not reliably predict tolerance in hand or face transplants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

18 people

The number who actually took part.

Start date

Oct 2013

Finished

Jul 2014

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with Hand (unilateral/bilateral) or face allotransplantation for at least one year * Patient without clinical sign of acute rejection at inclusion * Patient who signed the informed protocol consent * Patient older than 18 years old * Patient covered by an health insurance * Patient without legal protection Exclusion Criteria: * Patient with Hand or face allotransplantation for less than one year * Patient with clinical sign of acute rejection at inclusion * Unsigned protocol consent * Patient under the age of 18 years old

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hand and face allotransplantation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hand and face allotransplantation

Contacts and locations

Locations

  • Hospices Civils de Lyon

    Lyon, 69003, France